Modern glass office building at dusk

12+ Years · Regulatory Affairs CMC

Edward Regulatory
Consulting

Expert CMC regulatory strategy across submission, clinical trials, and pre- & post-approval lifecycle. Turning complex dossiers into first-cycle approvals for FDA and EMA.

12+
Years experience
FDA · EMA
Submissions
CMC
Specialism

Core Expertise

Depth across the full CMC regulatory lifecycle

CMC Submissions

Authoring and lifecycle management of CMC dossiers (Module 3, eCTD) for INDs, NDAs, MAAs and variations across FDA and EMA.

Clinical Trials

CMC support for IND/IMPD filings, trial-phase appropriate documentation, and CTA maintenance through development.

Pre & Post Approval

Strategy through approval and beyond — variations, change control, supplements and post-market commitments.

Submission Readiness

Dossier health checks, gap closure and agency-meeting preparation to ensure first-cycle approval confidence.

Hannah Edward, Regulatory Affairs CMC Consultant

About

Hannah Edward

Fractional CMC Regulatory Affairs Consultant

With over twelve years dedicated to Chemistry, Manufacturing and Controls (CMC) regulatory affairs, I help biotech and pharmaceutical teams navigate the most technically demanding parts of the submission journey — from first-in-human through marketing approval and beyond.

My focus spans submission authoring, clinical trial CMC support, and pre- and post-approval lifecycle management. I partner closely with quality, manufacturing and clinical teams to build dossiers that withstand FDA and EMA scrutiny — and to close the gaps that delay approvals.

“Submission readiness isn’t a milestone — it’s a discipline. My job is to make sure nothing surprises you, and nothing surprises the agency.”

12+ years in Regulatory Affairs CMC
FDA & EMA submission experience (eCTD)
IND · IMPD · NDA · MAA · Variations
Pre & post-approval lifecycle management
Download Capability Statement

Services

From gap to green light

Three focused engagements designed to de-risk your regulatory path — whether you need a diagnostic, an action plan, or a strategy to brief your board.

Gap Analysis

Know exactly where you stand

A rigorous, line-by-line review of your CMC dossier and quality documentation against current FDA/EMA expectations — surfacing deficiencies before the agency does.

  • Module 3 / eCTD completeness review
  • Health-authority guidance benchmarking
  • Risk-rated findings register
  • Prioritised, evidence-based summary

Remediation Roadmap

A clear path to compliant

A sequenced, resourced action plan that turns gaps into closed items — with owners, timelines and submission-ready deliverables.

  • Prioritised remediation backlog
  • Owner & timeline mapping
  • Submission-ready deliverables

Regulatory Strategy Brief

Decisions, de-risked

A concise, board-ready strategy document outlining the optimal regulatory pathway, agency interactions and CMC milestones for your asset.

  • Pathway & filing strategy
  • Agency engagement plan
  • CMC milestone mapping

Results Delivered

Measurable impact across global portfolios

25%Reduction in PDM update cycle timeProcess redesign across multi-market portfolios spanning solid dose, biologics and sterile products at Pfizer.
15%Reduction in portfolio maintenance cycle timeDrug portfolio maintenance efficiency gains delivered at Viatris.
617+Submissions of Fragmin to Health AuthoritiesLed a team of eight to completion across 2021–2023.
COVID-19Vaccine booster programmeContributed to CMC post-approval submissions for the booster programme.
Global submissions
EMEAUnited StatesCanadaAPACLatin America

Experience

A decade-plus of regulatory milestones

Twelve years building, defending and advancing CMC submissions across the full product lifecycle.

Nov 2016 — Dec 2017

Allergan

CMC regulatory affairs — authoring and maintaining submission documentation and supporting lifecycle activities across the product portfolio.

Dec 2017 — May 2019

Pfizer · Regional Regulatory CMC

Regional CMC regulatory affairs across multi-market portfolios spanning solid dose, biologics and sterile products.

May 2019 — Jul 2024

Pfizer · Regulatory CMC (RCM)

Drove a 25% reduction in PDM update cycle time through process redesign; led a team of eight delivering 617+ Fragmin submissions to Health Authorities (2021–2023); and contributed to CMC post-approval submissions for the COVID-19 vaccine booster programme.

Jul 2024 — Jan 2026

Viatris

Delivered a 15% reduction in drug portfolio maintenance cycle time, supporting global submissions across EMEA, US, Canada, APAC and Latin America.

Jan 2026 — Present

Edward Regulatory Consulting

Independent fractional CMC regulatory affairs consultant — advising biotech and pharma on submission strategy, gap analysis, remediation roadmaps and pre & post-approval lifecycle management.

Book a Consultation

Let’s talk about your submission

Choose a date and time that suits you (all times GMT). I’ll confirm your consultation and come prepared to discuss your programme.

Pick a date

SuMoTuWeThFrSa

Available slots (GMT)

Select a date to see available times.

Your details

No slot selected yet — pick a date and time on the left.